quizartinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Acute Myeloid Leukemia

Pending FDA approval for relapsed or resistant acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (r/r FLT3-ITD AML)

Next:

Pharmacology

Mechanism of Action

Inhibits FMS-like tyrosine kinase 3 (FLT3), and thereby, inhibits FLT3 receptor signally and proliferation in cells exogenously expressing FLT3

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.